Iranian Journal of Medical Sciences

Document Type: Brief Report(s)


1 Department of Hematology, School of Medical Sciences, Tarbiat Modares University, Tehran, Iran

2 Department of Pathology, School of Medicine, Shiraz University of Medical Sciences,Shiraz,Iran

3 Transplant Research Center, Nemazee Teaching Hospital, Shiraz University of Medical Sciences,Shiraz,Iran

4 Department of Genetics, Faculty of Basic Sciences, Tarbiat Modares University, Tehran, Iran


Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma. MicroRNAs (miRNAs) are endogenous small RNA, which can regulate gene expression at the post-transcriptional level. MiRNA profiling has shown a great potential as novel diagnostic and prognostic biomarkers. The present study was performed at the Nemazee Teaching Hospital (Shiraz, Iran) from 2011 to 2013.The aim of this study was to assess the deregulation of miRNAs profiles in DLBL against hyperplasic reactive lymph node as a normal. This could serve as a biomarker for DLBL. The miRCURY LNATM microarray was used on the total RNA, which was extracted from formalin-fixed paraffin-embedded tissue of 24 de novo diffuse large B-cell lymphoma patients and 14 normal lymph nodes. The greatest changes were detected in miR-4284 and miR-4484 level in patient’s lymphoma samples. These miRNAs can act as a diagnostic biomarker for DLBL.


  1. Macfarlane LA, Murphy PR. MicroRNA: Biogenesis, Function and Role in Cancer. Curr Genomics. 2010;11:537-61. doi: 10.2174/138920210793175895. PubMed PMID: 21532838; PubMed Central PMCID: PMC3048316.
  2. Pillai RS. MicroRNA function: multiple mechanisms for a tiny RNA? RNA. 2005;11:1753-61. doi: 10.1261/rna.2248605. PubMed PMID: 16314451; PubMed Central PMCID: PMC1370863.
  3. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6:857-66. doi: 10.1038/nrc1997. PubMed PMID: 17060945.
  4. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275-82. doi: 10.1182/blood-2003-05-1545. PubMed PMID: 14504078.
  5. Rai D, Karanti S, Jung I, Dahia PL, Aguiar RC. Coordinated expression of microRNA-155 and predicted target genes in diffuse large B-cell lymphoma. Cancer Genet Cytogenet. 2008;181:8-15. doi: 10.1016/j.cancergencyto.2007.10.008. PubMed PMID: 18262046; PubMed Central PMCID: PMC2276854.
  6. Roehle A, Hoefig KP, Repsilber D, Thorns C, Ziepert M, Wesche KO, et al. MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas. Br J Haematol. 2008;142:732-44. doi: 10.1111/j.1365-2141.2008.07237.x. PubMed PMID: 18537969.
  7. Xi Y, Nakajima G, Gavin E, Morris CG, Kudo K, Hayashi K, et al. Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA. 2007;13:1668-74. doi: 10.1261/rna.642907. PubMed PMID: 17698639; PubMed Central PMCID: PMC1986820.
  8. Stenvang J, Silahtaroglu AN, Lindow M, Elmen J, Kauppinen S. The utility of LNA in microRNA-based cancer diagnostics and therapeutics. Semin Cancer Biol. 2008;18:89-102. doi: 10.1016/j.semcancer.2008.01.004. PubMed PMID: 18295505.
  9. Zhang L, Zhou F, Garcia de Vinuesa A, de Kruijf EM, Mesker WE, Hui L, et al. TRAF4 promotes TGF-beta receptor signaling and drives breast cancer metastasis. Mol Cell. 2013;51:559-72. doi: 10.1016/j.molcel.2013.07.014. PubMed PMID: 23973329.
  10. Ikushima H, Miyazono K. TGFbeta signalling: a complex web in cancer progression. Nat Rev Cancer. 2010;10:415-24. doi: 10.1038/nrc2853. PubMed PMID: 20495575.
  11. Bueno MJ, Malumbres M. MicroRNAs and the cell cycle. Biochim Biophys Acta. 2011;1812:592-601. doi: 10.1016/j.bbadis.2011.02.002. PubMed PMID: 21315819.
  12. Sandhu SK, Croce CM, Garzon R. Micro-RNA Expression and Function in Lymphomas. Adv Hematol. 2011;2011:347137. doi: 10.1155/2011/347137. PubMed PMID: 21461378; PubMed Central PMCID: PMC3063410.
  13. Culpin RE, Proctor SJ, Angus B, Crosier S, Anderson JJ, Mainou-Fowler T. A 9 series microRNA signature differentiates between germinal centre and activated B-cell-like diffuse large B-cell lymphoma cell lines. Int J Oncol. 2010;37:367-76. PubMed PMID: 20596664.
  14. Zheng RL, Jiang YJ, Wang X. Role of microRNAs on therapy resistance in Non-Hodgkin's lymphoma. Int J Clin Exp Med. 2014;7:3818-32. PubMed PMID: 25550890; PubMed Central PMCID: PMC4276148.
  15. Kwanhian W, Lenze D, Alles J, Motsch N, Barth S, Doll C, et al. MicroRNA-142 is mutated in about 20% of diffuse large B-cell lymphoma. Cancer Med. 2012;1:141-55. doi: 10.1002/cam4.29. PubMed PMID: 23342264; PubMed Central PMCID: PMC3544448.